Share Name Share Symbol Market Type Share ISIN Share Description
Ideagen LSE:IDEA London Ordinary Share GB00B0CM0C50 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 89.00p 88.00p 90.00p 89.00p 89.00p 89.00p 76,399 07:37:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 21.9 1.0 0.7 120.3 176.32

Ideagen (IDEA) Latest News

More Ideagen News
Ideagen Takeover Rumours

Ideagen (IDEA) Share Charts

1 Year Ideagen Chart

1 Year Ideagen Chart

1 Month Ideagen Chart

1 Month Ideagen Chart

Intraday Ideagen Chart

Intraday Ideagen Chart

Ideagen (IDEA) Discussions and Chat

Ideagen (IDEA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-04-26 15:18:5288.5013,98812,379.38O
2017-04-26 15:06:2389.38912815.10O
2017-04-26 13:49:2289.4124,67022,057.94O
2017-04-26 11:31:1490.002,1421,927.80O
2017-04-26 11:24:1788.72800709.76O
View all Ideagen trades in real-time

Ideagen (IDEA) Top Chat Posts

DateSubject
26/4/2017
09:20
Ideagen Daily Update: Ideagen is listed in the Software & Computer Services sector of the London Stock Exchange with ticker IDEA. The last closing price for Ideagen was 89p.
Ideagen has a 4 week average price of 75.50p and a 12 week average price of 67.50p.
The 1 year high share price is 90.50p while the 1 year low share price is currently 49.50p.
There are currently 198,117,442 shares in issue and the average daily traded volume is 122,898 shares. The market capitalisation of Ideagen is £176,324,523.38.
25/4/2017
14:01
pj 1: FWIW Stockopedia has IDEA on a historic (April) 2016 p/e/ of x126 against normalised eps of 0.71p. I would note that IDEA's share price at April 2016 was 53p against 89p today. IMO the 2016 p/e is worthless as a comparator as there have been at least 3 eps upgrades following acquisitions and Broker reports since. Apples and Oranges?
23/3/2017
07:16
rivaldo: Big £10m earnings-enhancing acquisition - and funded by a placing at 75p :o)) I suspect the share price will soon be back to 78p-80p. Based on the PBT figures for 2015, I suspect the 2016 figures see PleaseTech acquired on a historic P/E of only 9 or 10. By the time the CEO and CFO leave during the coming year to 30/4/18, and with other savings etc, the P/E will probably drop even further. Lots of recurring income, and high overseas income too, which should bring in currency benefits this year. The placing was also oversubscribed enough to allow the CEO and some directors to slot some options and shares, which I don't begrudge at all given their success over time. Excellent news all round.
22/2/2017
08:30
jimbobaroony: Wonder what it could be? nothing considered share price sensitive surely, as that would be frowned on by the regulators
29/12/2016
11:26
pj 1: Here you go Rivaldo, I think a week is safe enough time to leave before posting to be fair to other subscribers. Ideagen (IDEA:AIM) Share price: 64.25p Market cap: £117m EPS Apr 2017: 3.2 PE Apr 2017: 20 Dividend Apr 2017: 0.2p Dividend yield: 0.3% Source: Shares, FinnCap Life sciences 3 There’s a net of rules, regulations and red tape tightening over many industries. Little UK software supplier Ideagen (IDEA:AIM) has a wide range of off-the-shelf specialised software tools smack bang in this, albeit unglamorous, sweet spot. The Midlands-based company concentrates on what it calls the governance, risk and compliance (GRC) space, providing information management solutions to highly regulated industries. Target markets include healthcare, complex manufacturing, banking/finance, defence and energy. Ideagen supplies an integrated system that combines information from multiple operational sources on top of the typical internal audit and compliance functions. This provides clients with a detailed overview of corporate risk, controls and consequence mitigation analysis. That’s an increasingly compelling sale once an organisation begins to grasp the significant financial and reputational damage potential of not having adequate systems in place. Cover IDEAGEN 221216 Loyal fans We’ve been fans of the company since it gravitated to AIM from the old Plus Markets in 2012, first flagging the investment opportunity at 16p in August that year. The company hasn’t put a foot wrong ever since; adding carefully vetted bolt-on acquisitions to its underlying progress. Three acquisitions have been made since summer 2016 alone, being Covalent, Logen and IPI Solutions. Full year results to 30 April 2016 revealed a 52% revenue jump to £21.9 million including respectable 10% organic growth. That led to a 57% leap in adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) to £6.3 million and improved operating cash conversion metrics. Shareholders should feel rightly chuffed about a 96% client renewals hit rate and 100 new customers won during that year. Ideagen also won its biggest single contract ever, worth £4.9 million. We believe the scale of new business is also improving. Healthy and wealthy A trading update in November implies the business is still in excellent health. We’ll find out more when half year results are published in January. FinnCap forecasts pre-tax profit rising by 21% to £6.9m for the full year to April 2017 – and then advancing to £8.4m a year later. It is also worth noting that Ideagen could potentially benefit from Brexit as that will increase red tape. Companies will need to comply with existing EU and international standards as well as the potential for the implementation of UK standards. (SF)
09/12/2016
07:12
multibagger: Cracking acquisition - seems to be a perfect acquisition fit :) I would expect the market to like this and add 2-3p to the share price today or the next few days ! Good luck all :)
07/12/2016
13:52
rivaldo: The share price could carry on rising up to 80p. Or it might fall back a bit. Who knows? If you're a short-term trader you might care, but otherwise....
22/8/2016
10:19
rivaldo: IDEA have been featured in Shares Magazine as follows - personally I believe 100p will come quicker than 3-4 years given the likelihood of more and bigger acquisitions, as well as organic growth: "Bright Ideagen Compliance and risk is a software niche being successfully tapped Increasing industry compliance, accountability, audit trails and risk management, organisations around the world are being pushed to embrace an ever-tightening red tape net. Little UK software specialist Ideagen (IDEA:AIM) has a wide range of off-theshelf specialised software tools smack bang in this sweet spot, and successful execution of its buy-and-build strategy should see the shares hit 70p in the next six to 12 months. The Midlands-based company concentrates on what it calls the governance, risk and compliance (GRC) space, providing information management solutions to highly regulated industries, such as healthcare, complex manufacturing, banking/finance, defence and energy. Supplying an integrated system that combines information from multiple operational sources on top of the typical internal audit and compliance functions, this leads to a detailed overview for clients of corporate risk, controls and consequence mitigation, an increasingly compelling sale once an organisation’s bosses begin to grasp the significant financial and reputational damage risk of not having adequate systems in place. PROFITABLE NICHE It’s not a particularly glamorous market in the way that, say cyber security or fintech is right now. But it is allowing the company to carve itself a successful growth path in this complex and profitable niche, with carefully-vetted acquisitions adding extra value. Ideagen secured its first major purchase back in December 2012 (£18 million Gael) but its has added other smaller bolt-ons since, including the £3.6 million (net of cash) purchase of peer Covalent. It adds compliance-heavy verticals (local government, social housing) plus a deeper footprint in the existing NHS market, bolstering recurring revenue streams to about 55% of its total going forward. And a good value bit of business it looks. An estimated 85% of Covalent’s £2.2 million most recent annual revenue is recurring, implying a purchase price of just 1.9-times those repeat sales. EYE ON VALUE It’s a typical Ideagen sort of deal and underlines the management ethos that is delivering carefully managed, rather than blistering, growth. To illustrate the point, Ideagen’s most recent full year results, to 30 April 2016, show a 52% jump in revenues to £21.9 million for the year to 30 April, 10% of which was driven from the underlying business, or organic growth in other words. This led to a 57% leap in adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) to £6.3 million and improved operating cash conversion metrics, an increasingly meaningful metric in the current minvestment climate. At a pre-tax profit level the figures shot up 58% to £5.7 million, although that’s after adjusting for various perceived one-offs, such as share based payments, amortisation of acquisition intangibles and a few other bits and bobs. Investors can feel rightly chuffed about a 96% client renewals hit rate and 100 new customers won, not to mention the biggest single contract in the company’s history secured, worth £4.9 million. A previous Play of the Week in the early days of the company’s switch from the old Plus market to AIM at 16p (2 Aug 2012), that investment call went on to rack up a near 30% gain in a year to 20.625p. As the chart shows, despite a few lumps and bumps along the way, share price progress has been pretty consistent ever since, the stock earning a typical high-teens to low 20s price to earnings (PE) multiple. Extrapolate a rough 20-times PE beyond this year into the 30 April 2018 fiscal period, investors can quite reasonably expect the shares to nudge 70p over the next six to 12 months, tallying with the 69p price target of analysts at FinnCap. But being a long-run growth opportunity, it is not out of the question for Ideagen stock to touch 100p on a three to four year view. Growth: MEDIUM Serving an expanding niche and is aligning its ambitions with the large opportunity without overstepping its resources. Risk: LOW A clear focus provides opportunity as well as raising barriers to entry for competitors. Quality: HIGH High visibility from recurring revenues and decent cash generation, risk to forecasts is typically on the upside."
20/11/2015
14:20
aceofthepack: 8 million shares! The share price hasn't budged. Am I missing something?
17/9/2015
08:35
rivaldo: Dilip/GHF, it's also worth factoring in to calculations that IDEA have a fast-growing cash pile - £5.3m at 30/4/15 - to incorporate into any share price targets, not least because I'm sure IDEA are on the lookout for more earnings-enhancing acquisitions. Nice plug from Penny Share Pro's e-mailed newsletter this morning: "Ideagen lands new contracts Ideagen, a leading supplier of information management software, recently announced it’s won two new deals with a combined value of £1 million. The contracts, one with a top 4 global accounting firm and the other with a leading global petrochemicals group, are for Ideagen's Governance Risk and Compliance products. It’s another very positive step forward for the group as it continues to expand its customer base and global footprint. In our view, it shouldn’t be too long before the shares break out of their current trading range and begin a fresh leg higher."
31/7/2015
10:22
rivaldo: Shares Mag are positive this week about IDEA: "Ideagen eyes record breakers Red tape software firm anticipates new business scale-up COMPLIANCE AND RISK management software supplier Ideagen (IDEA:AIM) hopes to beat its biggest contract success to date with the help of public cloud platform, Amazon Web Services (AWS). Ideagen’s software-as-a-service (SaaS) AWS-based risk and compliance toolset is called Enlighten and analysts believe it will be fundamental to the company scaling up its new business victories, and should drive the 47p share price higher. The UK Government remains committed to its ‘paperless NHS’ initiative, launched in 2013 under the previous coalition leadership, but largely driven by current conservative Secretary of State for Health, Jeremy Hunt. The aim is for a completely digitised patient records system by 2018, an objective that provides huge new business opportunities for Peak District-based Ideagen, as will expansion in other verticals, say analysts. ‘With the sales and marketing teams integrated into a single entity, management anticipates opportunities to cross-sell the group’s capabilities into existing clients and win new clients in the aviation, defence, transport and healthcare markets,’ spells out Michael Larner, an analyst at IT consultancy website TechMarketViews. Ideagen’s biggest single win to date is the £1 million deal with the Doncaster and Bassetlaw NHS Trust secured on 2 October 2014. SHARES SAYS: Rising red tape remains a big growth engine for the small cap."
Ideagen share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170426 23:31:52